Detailed valuation of an almost-partnered clinical program in oncology

Situation

• Our client was the R&D arm of a diversified company with several programs in the pipeline and significant cash requirements that were difficult for the parent company to handle
• Bionest was mandated to perform a valuation of the pipeline to support ongoing funding/partnering negotiations

Bionest Contribution

• Bionest performed an independent valuation of the programs

1. Full DCF analysis
2. Benchmark analysis including comparable companies and preceding sector acquisitions

• Bionest issued independent recommendations regarding the various company projects

1. Including key time-based value inflection points

Key Results

• The company was provided with all the tools required to justify the company valuation in front of potential investors and partners